Annovis Bio, Inc. (NYSE: ANVS) reported financial results for the third quarter ended September 30, 2026, and provided corporate updates regarding its clinical trials for buntanetap, an investigational oral therapy for neurodegenerative diseases.
Regarding its Alzheimer’s disease Phase 3 DUET-AD trial, the company confirmed that the last patient, last visit of the 6-month treatment period is scheduled for December 31, 2026. Database lock is expected on February 8, 2027, with topline results anticipated in March 2027. The trial is fully enrolled, comprising 862 patients with early Alzheimer’s disease (MMSE 20-28) who are positive for the plasma biomarker pTau217. The company plans to present the 6-month data at the AD/PD 2027 conference in Barcelona.
In Parkinson’s disease, the open-label extension (OLE-PD) study has enrolled 326 patients, with enrollment projected to close on January 29, 2027. The OLE-AD study, which allows patients from DUET-AD to continue treatment, is expected to begin enrolling rollover patients by the end of November 2026.
On the financial front, Annovis raised $21.0 million in gross proceeds through an underwritten public offering closed on November 6, 2026. The Chairman of the Board contributed $5.0 million as part of this offering. As of September 30, 2026, the company reported cash and cash equivalents totaling $2.8 million, compared to $19.5 million as of December 31, 2025. Research and development expenses for the third quarter of 2026 were $15.8 million, compared to $6.3 million in the same period in 2025. The company reported a net loss of $9.5 million for the quarter, or $0.22 per share.
